| 9.03 0.01 (0.11%) | 03-13 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.53 | 1-year : | 13.47 |
| Resists | First : | 9.88 | Second : | 11.53 |
| Pivot price | 8.98 |
|||
| Supports | First : | 8.79 | Second : | 8.11 |
| MAs | MA(5) : | 9.22 |
MA(20) : | 8.9 |
| MA(100) : | 7.63 |
MA(250) : | 7.79 |
|
| MACD | MACD : | 0.1  |
Signal : | 0.1 |
| %K %D | K(14,3) : | 55.1 |
D(3) : | 66.9 |
| RSI | RSI(14): 53.3 |
|||
| 52-week | High : | 11.52 | Low : | 5.55 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NVCT ] has closed below upper band by 46.0%. Bollinger Bands are 11.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.18 - 9.23 | 9.23 - 9.28 |
| Low: | 8.81 - 8.86 | 8.86 - 8.91 |
| Close: | 8.96 - 9.03 | 9.03 - 9.1 |
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. It develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate to inhibit the Proto-oncogene c-Src and YES1 kinases. The company was incorporated in 2020 and is based in Fort Lee, New Jersey.
Fri, 20 Feb 2026
(NVCT) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Wed, 11 Feb 2026
Nuvectis Pharma, Inc. SEC 10-K Report - TradingView
Wed, 11 Feb 2026
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights - GlobeNewswire
Fri, 09 Jan 2026
We Think Nuvectis Pharma (NASDAQ:NVCT) Can Afford To Drive Business Growth - simplywall.st
Wed, 19 Nov 2025
Nuvectis Pharma Inc. (NVCT) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 26 (M) |
| Shares Float | 15 (M) |
| Held by Insiders | 41.5 (%) |
| Held by Institutions | 17.1 (%) |
| Shares Short | 1,650 (K) |
| Shares Short P.Month | 1,620 (K) |
| EPS | -1.33 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.72 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -68.5 % |
| Return on Equity (ttm) | -188.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -7 (M) |
| PE Ratio | -6.85 |
| PEG Ratio | 0 |
| Price to Book value | 12.54 |
| Price to Sales | 0 |
| Price to Cash Flow | -14.95 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|